Zhenhao Liu

Dr. Zhenhao Liu

Shanghai Institute for Biomedical and Pharmaceutical Technologies, Shanghai, China
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 July 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
JXJiliang Xia
Jiliang Xia
JZJingyu Zhang
Jingyu Zhang
XWXuan Wu
Xuan Wu
WDWanqing Du
Wanqing Du
YZYinghong Zhu
Yinghong Zhu
WZWen Zhou
Wen Zhou
Metabolites in the tumor microenvironment are a critical factor for tumor progression. However, the lack of knowledge about the metabolic profile in the bone marrow (BM) microenvironment of multiple myeloma (MM) limits our understanding of MM progression. Here, we show that the glycine concentration in the BM microenvironment is elevated due to bone collagen degradation mediated by MM cell-secreted matrix metallopeptidase 13 (MMP13), while the elevated glycine level is linked to MM progression. MM cells utilize the channel protein solute carrier family 6 member 9 (SLC6A9) to absorb extrinsic glycine subsequently involved in the synthesis of glutathione (GSH) and purines. Inhibiting glycine utilization via SLC6A9 knockdown or the treatment with betaine suppresses MM cell proliferation and enhances the effects of bortezomib on MM cells. Together, we identify glycine as a key metabolic regulator of MM, unveil molecular mechanisms governing MM progression, and provide a promising therapeutic strategy for MM treatment.

1 June 2018 in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
Verified
Journal Article
Closed access
ZLZhenhao Liu
Zhenhao Liu
BLBao-Feng Lian
Bao-Feng Lian
QDQiong-Zhu Dong
Qiong-Zhu Dong
HSHan Sun
Han Sun
JWJin-Wang Wei
Jin-Wang Wei
LQLunxiu Qin
Lunxiu Qin

13 April 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
CKChunmei Kuang
Chunmei Kuang
MXMeijuan Xia
Meijuan Xia
GAGang An
Gang An
CLCuiCui Liu
CuiCui Liu
CHCong Hu
Cong Hu
WZWen Zhou
Wen Zhou
Thrombocytopenia is a major complication in a subset of patients with multiple myeloma (MM). However, little is known about its development and significance during MM. Here, we show thrombocytopenia is linked to poor prognosis in MM. In addition, we identify serine, which is released from MM cells into the bone marrow microenvironment, as a key metabolic factor that suppresses megakaryopoiesis and thrombopoiesis. The impact of excessive serine on thrombocytopenia is mainly mediated through the suppression of megakaryocyte (MK) differentiation. Extrinsic serine is transported into MKs through SLC38A1 and downregulates SVIL via SAM-mediated tri-methylation of H3K9, ultimately leading to the impairment of megakaryopoiesis. Inhibition of serine utilization or treatment with TPO enhances megakaryopoiesis and thrombopoiesis and suppresses MM progression. Together, we identify serine as a key metabolic regulator of thrombocytopenia, unveil molecular mechanisms governing MM progression, and provide potential therapeutic strategies for treating MM patients by targeting thrombocytopenia.

1 April 2015 in Gene
Verified
Journal Article
Closed access
HLHuifen Liu
Huifen Liu
XMXingjiang Mu
Xingjiang Mu
LGLang Gui
Lang Gui
MSMaoliang Su
Maoliang Su
HLHong Li
Hong Li
JZJunbin Zhang
Junbin Zhang

25 August 2021 in Journal of Agricultural and Food Chemistry
Verified
Journal Article
Closed access
HLHao Liu
Hao Liu
Jun LiuJun Liu
Jun Liu
ZLZhenhao Liu
Zhenhao Liu
QWQi Wang
Qi Wang
JLJunqiang Liu
Junqiang Liu
JZJun Zou
Jun Zou

28 April 2022 in Genes
Verified
Journal Article
Open access
PDF file
CLChunyu Liu
Chunyu Liu
YZYu Zhang
Yu Zhang
XJXingxing Jian
Xingxing Jian
XTXiaoxiu Tan
Xiaoxiu Tan
MLManman Lu
Manman Lu
LXLu Xie
Lu Xie
A proteogenomics-based neoantigen prediction pipeline, namely ProGeo-neo, was previously developed by our team to predict neoantigens, allowing the identification of class-I major histocompatibility complex (MHC) binding peptides based on single-nucleotide variation (SNV) mutations. To improve it, we here present an updated pipeline, i.e., ProGeo-neo v2.0, in which a one-stop software solution was proposed to identify neoantigens based on the paired tumor-normal whole genome sequencing (WGS)/whole exome sequencing (WES) data in FASTQ format. Preferably, in ProGeo-neo v2.0, several new features are provided. In addition to the identification of MHC-I neoantigens, the new version supports the prediction of MHC class II-restricted neoantigens, i.e., peptides up to 30-mer in length. Moreover, the source of neoantigens has been expanded, allowing more candidate neoantigens to be identified, such as in-frame insertion-deletion (indels) mutations, frameshift mutations, and gene fusion analysis. In addition, we propose two more efficient screening approaches, including an in-group authentic neoantigen peptides database and two more stringent thresholds. The range of candidate peptides was effectively narrowed down to those that are more likely to elicit an immune response, providing a more meaningful reference for subsequent experimental validation. Compared to ProGeo-neo, the ProGeo-neo v2.0 performed well based on the same dataset, including updated functionality and improved accuracy.